Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study
| Autor: | Jiunn-Song Jiang, Chen-Chun Lin, Diana Yu-Wung Yeh, Ching-Yuan Cheng, Shang-Jyh Kao, Wei-Wei Ng |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male Lung Neoplasms Physiology Afatinib Kinase Inhibitors Cancer Treatment Artificial Gene Amplification and Extension Biochemistry Lung and Intrathoracic Tumors Endocrinology Epidermal growth factor Carcinoma Non-Small-Cell Lung Medicine and Health Sciences Osimertinib heterocyclic compounds Epidermal growth factor receptor Enzyme Inhibitors Multidisciplinary biology Middle Aged Progression-Free Survival Neoplasm Proteins ErbB Receptors Survival Rate Deletion Mutation Medicine Female Erlotinib Tyrosine kinase medicine.drug Research Article Clinical Oncology medicine.medical_specialty Science Radiation Therapy Tyrosine Kinase Inhibitors Research and Analysis Methods Gefitinib Internal medicine Growth Factors medicine Genetics Humans Lung cancer Molecular Biology Techniques Protein Kinase Inhibitors Molecular Biology neoplasms Aged Retrospective Studies Endocrine Physiology Epidermal Growth Factor business.industry Cancers and Neoplasms Biology and Life Sciences medicine.disease Non-Small Cell Lung Cancer respiratory tract diseases Mutation biology.protein Enzymology Amplification-Refractory Mutation System Analysis Clinical Medicine business |
| Zdroj: | PLoS ONE, Vol 16, Iss 6, p e0253335 (2021) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | The sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) remains a matter of controversy. This cohort study analyzed the overall survival (OS) and progression-free survival (PFS) of afatinib compared with erlotinib and gefitinib first-line. EGFRm+, advanced NSCLC patients treated with either afatinib, erlotinib or gefitinib were retrospectively analyzed. A total of 107 patients were included. There was no statistically significant difference in PFS among the 3 groups. In the ≥ 60 years age group, the afatinib group had longer survival compared to the gefitinib group (p = 0.01). Median OS were 19.1, 22.9, and 35.6 months for gefitinib, erlotinib, and afatinib groups, respectively, with statistical significance between the gefitinib and afatinib groups (p = 0.009). Patients on afatinib also had longer median OS than erlotinib and gefitinib pooled together (35.5 versus 21.4 months; hazard ratio = 0.54, p = 0.016), despite similar median PFS. In conclusion, afatinib is a better choice compared to gefitinib or erlotinib for EGFRm+ patients. The OS obtained with afatinib is just 3 months shorter than osimertinib in the FLAURA trial. Direct comparison studies with osimertinib are still needed to determine optimal sequencing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|